344 related articles for article (PubMed ID: 36303101)
1. Clinical and Translational Advances in Glioma Immunotherapy.
Bunse L; Bunse T; Krämer C; Chih YC; Platten M
Neurotherapeutics; 2022 Oct; 19(6):1799-1817. PubMed ID: 36303101
[TBL] [Abstract][Full Text] [Related]
2. Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.
Scheetz L; Kadiyala P; Sun X; Son S; Hassani Najafabadi A; Aikins M; Lowenstein PR; Schwendeman A; Castro MG; Moon JJ
Clin Cancer Res; 2020 Aug; 26(16):4369-4380. PubMed ID: 32439701
[TBL] [Abstract][Full Text] [Related]
3. Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Sayour EJ; Grippin A; De Leon G; Stover B; Rahman M; Karachi A; Wummer B; Moore G; Castillo-Caro P; Fredenburg K; Sarkisian MR; Huang J; Deleyrolle LP; Sahay B; Carrera-Justiz S; Mendez-Gomez HR; Mitchell DA
Nano Lett; 2018 Oct; 18(10):6195-6206. PubMed ID: 30259750
[TBL] [Abstract][Full Text] [Related]
4. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
5. Current Immunotherapeutic Approaches for Malignant Gliomas.
Han MH; Kim CH
Brain Tumor Res Treat; 2022 Jan; 10(1):1-11. PubMed ID: 35118842
[TBL] [Abstract][Full Text] [Related]
6. Dendritic-cell- and peptide-based vaccination strategies for glioma.
Yamanaka R
Neurosurg Rev; 2009 Jul; 32(3):265-73; discussion 273. PubMed ID: 19214609
[TBL] [Abstract][Full Text] [Related]
7. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Blass E; Ott PA
Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
[TBL] [Abstract][Full Text] [Related]
8. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.
Akasaki Y; Black KL; Yu JS
Front Biosci; 2005 Sep; 10():2908-21. PubMed ID: 15970545
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
10. Peptide-based immunotherapeutic approaches to glioma: a review.
Yamanaka R; Itoh K
Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
[TBL] [Abstract][Full Text] [Related]
11. Clinical implication of cellular vaccine in glioma: current advances and future prospects.
Yan Y; Zeng S; Gong Z; Xu Z
J Exp Clin Cancer Res; 2020 Nov; 39(1):257. PubMed ID: 33228738
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside.
Roy S; Sethi TK; Taylor D; Kim YJ; Johnson DB
J Leukoc Biol; 2020 Oct; 108(4):1455-1489. PubMed ID: 32557857
[TBL] [Abstract][Full Text] [Related]
13. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for glioma: from illusion to realistic prospects?
Dietrich PY; Dutoit V; Walker PR
Am Soc Clin Oncol Educ Book; 2014; ():51-9. PubMed ID: 24857060
[TBL] [Abstract][Full Text] [Related]
15. Considerations for personalized neoantigen vaccination in Malignant glioma.
Dunn GP; Sherpa N; Manyanga J; Johanns TM
Adv Drug Deliv Rev; 2022 Jul; 186():114312. PubMed ID: 35487282
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapeutic approaches to glioma.
Yamanaka R
Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
[TBL] [Abstract][Full Text] [Related]
17. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell vaccines and immunity in glioma patients.
Wheeler CJ; Black KL
Front Biosci; 2005 Sep; 10():2861-81. PubMed ID: 15970541
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
20. The current state of immunotherapy for gliomas: an eye toward the future.
Fecci PE; Sampson JH
J Neurosurg; 2019 Sep; 131(3):657-666. PubMed ID: 31473668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
